Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors : Episode 2
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.
Video content above is prompted by the following:
- What are the standard treatment options for non–muscle-invasive bladder cancer (NMIBC)?
- What are the management options for patients with intermediate and high-risk NMIBC?
- Can you explain the mechanism of action of BCG treatment in stimulating the immune response against bladder cancer?
- In an ideal treatment paradigm with single-agent BCG, what are the best outcomes for patients with high-risk NMIBC?
- What are the rates of recurrence and progression?
- What do you feel the rates of progression are in the real world vs what you see in your practice?
Recent Videos
Related Content
